Crossmark Global Holdings Inc. Has $825,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Crossmark Global Holdings Inc. decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMNFree Report) by 3.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,924 shares of the life sciences company’s stock after selling 235 shares during the period. Crossmark Global Holdings Inc.’s holdings in Illumina were worth $825,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. HighTower Advisors LLC grew its position in shares of Illumina by 2.7% in the third quarter. HighTower Advisors LLC now owns 63,303 shares of the life sciences company’s stock valued at $8,685,000 after purchasing an additional 1,658 shares during the last quarter. Alliance Wealth Advisors LLC UT grew its holdings in Illumina by 5.4% in the 3rd quarter. Alliance Wealth Advisors LLC UT now owns 9,210 shares of the life sciences company’s stock valued at $1,264,000 after buying an additional 474 shares in the last quarter. Wilkins Investment Counsel Inc. bought a new position in Illumina during the 3rd quarter worth $2,128,000. Loomis Sayles & Co. L P lifted its holdings in shares of Illumina by 5.5% during the third quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock worth $550,212,000 after buying an additional 208,267 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its position in shares of Illumina by 18.2% in the third quarter. E Fund Management Co. Ltd. now owns 2,301 shares of the life sciences company’s stock valued at $316,000 after acquiring an additional 354 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of Illumina stock opened at $109.82 on Tuesday. The business’s fifty day simple moving average is $116.35 and its 200 day simple moving average is $127.44. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $212.49. The firm has a market capitalization of $17.49 billion, a P/E ratio of -13.47 and a beta of 1.20.

Illumina (NASDAQ:ILMNGet Free Report) last released its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.08 EPS. As a group, analysts anticipate that Illumina, Inc. will post 0.88 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Scotiabank dropped their price objective on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a research note on Monday, May 6th. Jefferies Financial Group initiated coverage on Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target on the stock. TD Cowen dropped their price objective on Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a report on Thursday, June 6th. Royal Bank of Canada reissued an “outperform” rating and set a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Finally, Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $161.24.

Read Our Latest Stock Analysis on Illumina

Illumina Company Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Recommended Stories

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.